BR112018076666A2 - cilastatina para uso no tratamento de sépsis - Google Patents

cilastatina para uso no tratamento de sépsis

Info

Publication number
BR112018076666A2
BR112018076666A2 BR112018076666-6A BR112018076666A BR112018076666A2 BR 112018076666 A2 BR112018076666 A2 BR 112018076666A2 BR 112018076666 A BR112018076666 A BR 112018076666A BR 112018076666 A2 BR112018076666 A2 BR 112018076666A2
Authority
BR
Brazil
Prior art keywords
sepsis
cilastatin
treatment
aki
methods
Prior art date
Application number
BR112018076666-6A
Other languages
English (en)
Inventor
Tejedor Jorge Alberto
Lazaro Fernandez Alberto
Humanes Sanchez Blanca
Angeles Gonzalez-Nicolas Gonzalez Maria
Original Assignee
Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón filed Critical Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón
Publication of BR112018076666A2 publication Critical patent/BR112018076666A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

a presente invenção se refere ao tratamento de sépsis e lesão renal aguda associada com a sépsis (sa-aki). mais especificamente, se refere à cilastatina para uso em um método de tratamento de sépsis e/ou sa-aki e redução de sua mortalidade associada, em um indivíduo mamífero. é ainda direcionada aos métodos para o tratamento de sépsis e/ou sa-aki; e às composições farmacêuticas para uso nos métodos da invenção.
BR112018076666-6A 2016-06-24 2017-06-23 cilastatina para uso no tratamento de sépsis BR112018076666A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382299 2016-06-24
EP16382299.2 2016-06-24
PCT/EP2017/065609 WO2017220810A1 (en) 2016-06-24 2017-06-23 Cilastatin for use in the treatment of sepsis

Publications (1)

Publication Number Publication Date
BR112018076666A2 true BR112018076666A2 (pt) 2019-04-02

Family

ID=56345070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076666-6A BR112018076666A2 (pt) 2016-06-24 2017-06-23 cilastatina para uso no tratamento de sépsis

Country Status (9)

Country Link
US (1) US11185522B2 (pt)
EP (1) EP3474897B1 (pt)
JP (1) JP7109791B2 (pt)
CN (1) CN109843330B (pt)
AU (1) AU2017281744B2 (pt)
BR (1) BR112018076666A2 (pt)
CA (1) CA3028846A1 (pt)
ES (1) ES2864168T3 (pt)
WO (1) WO2017220810A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999800A1 (en) 2015-08-11 2017-02-16 Stephen Mark Robbins Dpep-1 binding compositions and methods of use
WO2021221101A1 (ja) * 2020-04-30 2021-11-04 デンカ株式会社 シラスタチンを含有する液体製剤及び医薬製品
NL2025730B1 (en) 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
WO2022191828A1 (en) * 2021-03-10 2022-09-15 Wen Tan NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668504A (en) 1970-11-18 1987-05-26 Merck & Co., Inc. Use of substituted propenoates to prevent nephrotoxicity of certain antibiotics
WO1997037649A1 (en) 1996-04-04 1997-10-16 Merck & Co., Inc. Method of reducing nephrotoxicity
CN1878564A (zh) * 2003-09-12 2006-12-13 科罗拉多州大学评议会 用于治疗损伤的谷氨酰胺
WO2005037265A1 (ja) * 2003-10-17 2005-04-28 Mitsubishi Pharma Corporation 併用薬剤
US9216185B2 (en) * 2008-07-11 2015-12-22 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon Use of cilastatin to reduce nephrotatoxicity of various compounds
TWI558403B (zh) 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
CA2937311A1 (en) * 2014-01-24 2015-07-30 Ea Pharma Co., Ltd. Megalin antagonist
CA2999800A1 (en) 2015-08-11 2017-02-16 Stephen Mark Robbins Dpep-1 binding compositions and methods of use

Also Published As

Publication number Publication date
JP2019525954A (ja) 2019-09-12
JP7109791B2 (ja) 2022-08-01
EP3474897B1 (en) 2021-01-27
WO2017220810A1 (en) 2017-12-28
US11185522B2 (en) 2021-11-30
AU2017281744A1 (en) 2019-01-17
CN109843330B (zh) 2022-08-23
CN109843330A (zh) 2019-06-04
US20200069623A1 (en) 2020-03-05
ES2864168T3 (es) 2021-10-13
AU2017281744B2 (en) 2022-10-27
EP3474897A1 (en) 2019-05-01
CA3028846A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CO2017010618A2 (es) Anticuerpos contra icos
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
BR112018076666A2 (pt) cilastatina para uso no tratamento de sépsis
BR112015001768A2 (pt) método e dispositivo para processamento de modo infantil
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112018007809A2 (pt) composição de agente de resistência a seco, método para melhorar a força a seco de papel, e, uso de uma composição
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
BR112017001339A2 (pt) método, pasta de cimento e sistema
BR112015018948A2 (pt) produtos alimentícios com sódio reduzido
BR112018075135A2 (pt) combinações farmacêuticas para tratar câncer
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112012028668A2 (pt) emulsão, processo para preparar a emulsão, e, uso
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112017011916A2 (pt) agente para tratamento de deformação de cabelo
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]